# Split-course SBRT for Borderline Resectable and Locally Advanced Pancreatic Cancer

> **NCT04289792** · PHASE2 · UNKNOWN · sponsor: **Fujian Medical University Union Hospital** · enrollment: 27 (estimated)

## Conditions studied

- Pancreatic Neoplasms

## Interventions

- **DRUG:** nab-Paclitaxel+Gemcitabine
- **RADIATION:** split-course SBRT

## Key facts

- **NCT ID:** NCT04289792
- **Lead sponsor:** Fujian Medical University Union Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-09
- **Primary completion:** 2024-05-09
- **Final completion:** 2025-05-09
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2023-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04289792

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04289792, "Split-course SBRT for Borderline Resectable and Locally Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04289792. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*